Masaru Taniguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masaru Taniguchi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Toshinori Nakayama
Department of Immunology, Graduate School of Medicine Chiba University Chiba Japan
8 shared publications Michishige Harada
Laboratory for Immune Regulation|RIKEN Research Center for Allergy and Immunology
5 shared publicationsTetsu Kawano
CREST (Core Research for Evolutional Science and Technology) Project, JST, 4–1‐8 Honcho, Kawagu‐chi, Saitama 332–0012
4 shared publicationsShinichiro Motohashi
3 shared publicationsYoshikatsu Kaneko
3 shared publicationsHiroshi Wakao
Laboratory for Immune Regulation|RIKEN Research Center for Allergy and Immunology
2 shared publications
Latest Publications
- Open Access
- 1 February 2004
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 16 (2) , 215-222
Impaired IFN- production of V 24 NKT cells in non-remitting sarcoidosis
Sarcoidosis is a systemic disorder associated with granuloma characterized by an abnormal Th1‐type cytokine production and accumulation of Th1 CD4 T cells in the granuloma lesions, suggesting an importance of Th1 responses in sarcoidosis. However, the pathogenesis of sarcoidosis remains to be solved. Here, we investigated the nature of Vα24 NKT cells with immunoregulatory functions in sarcoidosis. Patients with non‐remitting sarcoidosis displayed a decrease in the number of Vα24 NKT cells in peripheral blood, but an accumulation of these cells in granulomatous lesions. When stimulated with the specific glycolipid ligand, α‐galactosylceramide, peripheral blood Vα24 NKT cells from patients with non‐remitting disease produced significantly less IFN‐γ than those from healthy volunteers, but normal levels of IL‐4. The reduced IFN‐γ production was observed only in Vα24 NKT cells and not conventional CD4 T cells, but was normal in patients with remitting disease, suggesting that non‐remitting sarcoidosis involves an insufficient IFN‐γ production of Vα24 NKT cells which is well correlated with disease activity. Thus, these results suggest that Vα24 NKT cells play a crucial role in the disease status of sarcoidosis.
- 1 February 2004
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 16 (2) , 215-222
Open AccessImpaired IFN- production of V 24 NKT cells in non-remitting sarcoidosis
Sarcoidosis is a systemic disorder associated with granuloma characterized by an abnormal Th1‐type cytokine production and accumulation of Th1 CD4 T cells in the granuloma lesions, suggesting an importance of Th1 responses in sarcoidosis. However, the pathogenesis of sarcoidosis remains to be solved. Here, we investigated the nature of Vα24 NKT cells with immunoregulatory functions in sarcoidosis. Patients with non‐remitting sarcoidosis displayed a decrease in the number of Vα24 NKT cells in peripheral blood, but an accumulation of these cells in granulomatous lesions. When stimulated with the specific glycolipid ligand, α‐galactosylceramide, peripheral blood Vα24 NKT cells from patients with non‐remitting disease produced significantly less IFN‐γ than those from healthy volunteers, but normal levels of IL‐4. The reduced IFN‐γ production was observed only in Vα24 NKT cells and not conventional CD4 T cells, but was normal in patients with remitting disease, suggesting that non‐remitting sarcoidosis involves an insufficient IFN‐γ production of Vα24 NKT cells which is well correlated with disease activity. Thus, these results suggest that Vα24 NKT cells play a crucial role in the disease status of sarcoidosis.
- 1 December 2003
- Published by Springer Nature in Nature Immunology
- Vol. 4 (12) , 1164-1165
The NKT cell system: bridging innate and acquired immunity
- 1 December 2003
- Published by Springer Nature in Nature Immunology
- Vol. 4 (12) , 1164-1165
The NKT cell system: bridging innate and acquired immunity
- 1 April 2003
- Published by Annual Reviews in Annual Review of Immunology
- Vol. 21 (1) , 483-513
The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response
A novel lymphocyte lineage, Vα14 natural killer T (NKT) cells, is now well established as distinct from conventional αβ T cells. Vα14 NKT cells express a single invariant Vα14 antigen receptor that is essential for their development. Successful identification of a specific ligand, α-galactosylceramide(α-GalCer), and the establishment of gene-manipulated mice with selective loss of Vα14 NKT cells helped elucidate the remarkable functional diversity of Vα14 NKT cells in various immune responses such as host defense by mediating anti-nonself innate immune reaction, homeostatic regulation of anti-self responses, and antitumor immunity.
- 1 April 2003
- Published by Annual Reviews in Annual Review of Immunology
- Vol. 21 (1) , 483-513
The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response
A novel lymphocyte lineage, Vα14 natural killer T (NKT) cells, is now well established as distinct from conventional αβ T cells. Vα14 NKT cells express a single invariant Vα14 antigen receptor that is essential for their development. Successful identification of a specific ligand, α-galactosylceramide(α-GalCer), and the establishment of gene-manipulated mice with selective loss of Vα14 NKT cells helped elucidate the remarkable functional diversity of Vα14 NKT cells in various immune responses such as host defense by mediating anti-nonself innate immune reaction, homeostatic regulation of anti-self responses, and antitumor immunity.
- Open Access
- 6 September 2002
- Published by Wiley in International Journal of Cancer
- Vol. 102 (2) , 159-165
Preserved IFN‐α production of circulating Vα24 NKT cells in primary lung cancer patients
Human Vα24 NKT cells bearing an invariant Vα24JαQ antigen receptor, the counterpart of murine Vα14 NKT cells, are activated by a specific ligand, α‐GalCer, in a CD1d‐dependent manner. Here, we demonstrate decreased numbers of circulating Vα24 NKT cells in patients with primary lung cancer compared to healthy volunteers. However, Vα24 NKT cells and DCs from lung cancer patients were functionally normal, even in the presence of tumor. Furthermore, levels of Vα24 NKT cells in surgically resected lung tissue appeared to be equivalent to those of Vα14 NKT cells in the mouse lung. Levels of Vα24 NKT cells in the tumor tissue itself were increased about 2.5 times. Administration of α‐GalCer‐pulsed DCs expanded Vα14 NKT cells in the lung more than 10 times, and the increased levels were sustained for 1 week. This may explain the previous finding that α‐GalCer‐pulsed DCs exerted strong antitumor activity in mouse lung tumor metastatic models. The potential use of α‐GalCer‐pulsed DCs for immunotherapy aimed at activating endogenous Vα24 NKT cells in the lung of cancer patients is discussed.
- 6 September 2002
- Published by Wiley in International Journal of Cancer
- Vol. 102 (2) , 159-165
Open AccessPreserved IFN‐α production of circulating Vα24 NKT cells in primary lung cancer patients
Human Vα24 NKT cells bearing an invariant Vα24JαQ antigen receptor, the counterpart of murine Vα14 NKT cells, are activated by a specific ligand, α‐GalCer, in a CD1d‐dependent manner. Here, we demonstrate decreased numbers of circulating Vα24 NKT cells in patients with primary lung cancer compared to healthy volunteers. However, Vα24 NKT cells and DCs from lung cancer patients were functionally normal, even in the presence of tumor. Furthermore, levels of Vα24 NKT cells in surgically resected lung tissue appeared to be equivalent to those of Vα14 NKT cells in the mouse lung. Levels of Vα24 NKT cells in the tumor tissue itself were increased about 2.5 times. Administration of α‐GalCer‐pulsed DCs expanded Vα14 NKT cells in the lung more than 10 times, and the increased levels were sustained for 1 week. This may explain the previous finding that α‐GalCer‐pulsed DCs exerted strong antitumor activity in mouse lung tumor metastatic models. The potential use of α‐GalCer‐pulsed DCs for immunotherapy aimed at activating endogenous Vα24 NKT cells in the lung of cancer patients is discussed.
- Open Access
- 1 April 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (4) , 397-403
Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
NKT cells, a novel murine lymphoid lineage bearing an invariant T cell receptor encoded by Vα14 and Jα281 gene segments, recognize a specific ligand glycolipid, α‐galactosylceramide (α‐GalCer) in a CDld‐dependent manner. Recent research has revealed that activated Vα14 NKT cells have dramatic antitumor effects against a wide variety of tumor cell lines in vivo and in vitro. Here, we demonstrate strong in vivo antitumor effects brought about by treatment with α‐GalCer‐pulsed dendritic cells in comparison with in vitro‐activated Vα14 NKT cells. Furthermore, we show a significant expansion of endogenous Vα14 NKT cells in the lung following the administration of α‐GalCer‐pulsed dendritic cells. The feasibility of immunotherapy with α‐GalCer‐pulsed dendritic cells is discussed.
- 1 April 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (4) , 397-403
Open AccessExpansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
NKT cells, a novel murine lymphoid lineage bearing an invariant T cell receptor encoded by Vα14 and Jα281 gene segments, recognize a specific ligand glycolipid, α‐galactosylceramide (α‐GalCer) in a CDld‐dependent manner. Recent research has revealed that activated Vα14 NKT cells have dramatic antitumor effects against a wide variety of tumor cell lines in vivo and in vitro. Here, we demonstrate strong in vivo antitumor effects brought about by treatment with α‐GalCer‐pulsed dendritic cells in comparison with in vitro‐activated Vα14 NKT cells. Furthermore, we show a significant expansion of endogenous Vα14 NKT cells in the lung following the administration of α‐GalCer‐pulsed dendritic cells. The feasibility of immunotherapy with α‐GalCer‐pulsed dendritic cells is discussed.
- 1 December 2000
- Published by Elsevier in Seminars in Immunology
- Vol. 12 (6) , 543-550
Recognition and function of Vα14 NKT cells
- 1 December 2000
- Published by Elsevier in Seminars in Immunology
- Vol. 12 (6) , 543-550
Recognition and function of Vα14 NKT cells
- Open Access
- 3 January 2000
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 191 (1) , 105-114
Augmentation of Vα14 Nkt Cell–Mediated Cytotoxicity by Interleukin 4 in an Autocrine Mechanism Resulting in the Development of Concanavalin a–Induced Hepatitis
The administration of concanavalin A (Con A) induces a rapid severe injury of hepatocytes in mice. Although the Con A–induced hepatitis is considered to be an experimental model of human autoimmune hepatitis, the precise cellular and molecular mechanisms that induce hepatocyte injury remain unclear. Here, we demonstrate that Vα14 NKT cells are required and sufficient for induction of this hepatitis. Moreover, interleukin (IL)-4 produced by Con A–activated Vα14 NKT cells is found to play a crucial role in disease development by augmenting the cytotoxic activity of Vα14 NKT cells in an autocrine fashion. Indeed, short-term treatment with IL-4 induces an increase in the expression of granzyme B and Fas ligand (L) in Vα14 NKT cells. Moreover, Vα14 NKT cells from either perforin knock-out mice or FasL-mutant gld/gld mice fail to induce hepatitis, and hence perforin–granzyme B and FasL appear to be effector molecules in Con A–induced Vα14 NKT cell–mediated hepatocyte injury.
- 3 January 2000
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 191 (1) , 105-114
Open AccessAugmentation of Vα14 Nkt Cell–Mediated Cytotoxicity by Interleukin 4 in an Autocrine Mechanism Resulting in the Development of Concanavalin a–Induced Hepatitis
The administration of concanavalin A (Con A) induces a rapid severe injury of hepatocytes in mice. Although the Con A–induced hepatitis is considered to be an experimental model of human autoimmune hepatitis, the precise cellular and molecular mechanisms that induce hepatocyte injury remain unclear. Here, we demonstrate that Vα14 NKT cells are required and sufficient for induction of this hepatitis. Moreover, interleukin (IL)-4 produced by Con A–activated Vα14 NKT cells is found to play a crucial role in disease development by augmenting the cytotoxic activity of Vα14 NKT cells in an autocrine fashion. Indeed, short-term treatment with IL-4 induces an increase in the expression of granzyme B and Fas ligand (L) in Vα14 NKT cells. Moreover, Vα14 NKT cells from either perforin knock-out mice or FasL-mutant gld/gld mice fail to induce hepatitis, and hence perforin–granzyme B and FasL appear to be effector molecules in Con A–induced Vα14 NKT cell–mediated hepatocyte injury.
- Open Access
- 1 September 1999
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 163 (5) , 2387-2391
Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with α-Galactosylceramide
A unique lymphoid lineage, Vα14 NKT cells, bearing an invariant Ag receptor encoded by Vα14 and Jα281 gene segments, play crucial roles in various immune responses, including protective immunity against malignant tumors. A specific ligand of Vα14 NKT cells is determined to be α-galactosylceramide (α-GalCer) which is presented by the CD1d molecule. Here, we report that dendritic cells (DCs) pulsed with α-GalCer effectively induce potent antitumor cytotoxic activity by specific activation of Vα14 NKT cells, resulting in the inhibition of tumor metastasis in vivo. Moreover, a complete inhibition of B16 melanoma metastasis in the liver was observed when α-GalCer-pulsed DCs were injected even 7 days after transfer of tumor cells to syngeneic mice where small but multiple metastatic nodules were already formed. The potential utility of DCs pulsed with α-GalCer for tumor immunotherapy is discussed.
- 1 September 1999
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 163 (5) , 2387-2391
Open AccessCutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with α-Galactosylceramide
A unique lymphoid lineage, Vα14 NKT cells, bearing an invariant Ag receptor encoded by Vα14 and Jα281 gene segments, play crucial roles in various immune responses, including protective immunity against malignant tumors. A specific ligand of Vα14 NKT cells is determined to be α-galactosylceramide (α-GalCer) which is presented by the CD1d molecule. Here, we report that dendritic cells (DCs) pulsed with α-GalCer effectively induce potent antitumor cytotoxic activity by specific activation of Vα14 NKT cells, resulting in the inhibition of tumor metastasis in vivo. Moreover, a complete inhibition of B16 melanoma metastasis in the liver was observed when α-GalCer-pulsed DCs were injected even 7 days after transfer of tumor cells to syngeneic mice where small but multiple metastatic nodules were already formed. The potential utility of DCs pulsed with α-GalCer for tumor immunotherapy is discussed.
- 12 May 1998
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (10) , 5690-5693
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
We have recently identified α-galactosylceramide (α-GalCer) as a specific ligand for an invariant Vα14/Vβ8.2 T cell receptor exclusively expressed on the majority of Vα14 NKT cells, a novel subset of lymphocytes. Here, we report that α-GalCer selectively activates Vα14 NKT cells resulting in prevention of tumor metastasis. The effector mechanisms of the ligand-activated Vα14 NKT cells seem to be mediated by natural killer (NK)-like nonspecific cytotoxicity. Indeed, the cytotoxic index obtained by α-GalCer-activated Vα14 NKT cells was reduced by the addition of cold target tumor cells or by treatment with concanamycin A, which inhibits activation and secretion of perforin, but not by mAbs against molecules involved in the NKT cell recognition and conventional cytotoxicity, such as CD1d, Vβ8, NK1.1, Ly49C, Fas, or Fas ligand. These results suggest that the ligand-activated Vα14 NKT cells kill tumor cells directly through a CD1d/Vα14 T cell receptor-independent, NK-like mechanism.
- 12 May 1998
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (10) , 5690-5693
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
We have recently identified α-galactosylceramide (α-GalCer) as a specific ligand for an invariant Vα14/Vβ8.2 T cell receptor exclusively expressed on the majority of Vα14 NKT cells, a novel subset of lymphocytes. Here, we report that α-GalCer selectively activates Vα14 NKT cells resulting in prevention of tumor metastasis. The effector mechanisms of the ligand-activated Vα14 NKT cells seem to be mediated by natural killer (NK)-like nonspecific cytotoxicity. Indeed, the cytotoxic index obtained by α-GalCer-activated Vα14 NKT cells was reduced by the addition of cold target tumor cells or by treatment with concanamycin A, which inhibits activation and secretion of perforin, but not by mAbs against molecules involved in the NKT cell recognition and conventional cytotoxicity, such as CD1d, Vβ8, NK1.1, Ly49C, Fas, or Fas ligand. These results suggest that the ligand-activated Vα14 NKT cells kill tumor cells directly through a CD1d/Vα14 T cell receptor-independent, NK-like mechanism.